TSX futures subdued as gold rally takes a breather
Investing.com - H.C. Wainwright has assumed coverage on NRx Pharmaceuticals (NASDAQ:NRXP) with a Buy rating and a $40.00 price target, according to a research note released Monday. The stock, which has surged 68.71% over the past year and 18.53% in the last week, currently trades at $2.75. Analyst targets range from $25 to $46, suggesting significant upside potential.
The firm cited NRx’s dual strategy combining therapeutics with mental health care delivery to address acute suicidality in depression, which it describes as "one of the most urgent unmet needs in psychiatry and a clear U.S. public health priority." According to InvestingPro analysis, which provides comprehensive insights through its Pro Research Reports covering 1,400+ stocks, the company maintains a FAIR financial health score of 2.12.
NRx’s two late-stage candidates—NRX-100 (intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone)—are advancing toward New Drug Application filings in 2025. In August 2025, NRX-100 received an expanded Fast Track designation covering all depression with suicidality, significantly increasing its addressable market.
The company filed an abbreviated New Drug Application for NRX-100 in general use in June 2025, with a potential FDA action date expected by year-end 2025. NRx also applied for the FDA Commissioner’s National Priority Voucher, which could reduce review timelines to as short as one to two months.
Beyond its drug pipeline, NRx’s wholly-owned subsidiary HOPE Therapeutics is developing a national network of neuroplastic-focused clinics targeting suicidality and post-traumatic stress disorder, with profitability targeted by year-end 2025. With a market capitalization of $65.37 million, analysts expect the company to achieve profitability this year, marking a significant milestone in its growth trajectory.
In other recent news, NRx Pharmaceuticals reported its financial results for Q2 2025, revealing a wider-than-expected loss. The company posted an earnings per share (EPS) of -$0.98, which was significantly below the forecasted -$0.53. This represents an EPS surprise of 84.91%. In addition, the U.S. Food and Drug Administration granted Fast Track designation for NRx’s NRX-100, a preservative-free ketamine treatment aimed at addressing suicidal ideation in depression, including bipolar depression. This designation allows the company to make NRX-100 available on an expanded access basis for patients with severe suicidal depression who have not responded to existing treatments. Moreover, D. Boral Capital raised its price target for NRx Pharmaceuticals from $31 to $34, maintaining a Buy rating on the stock. The adjustment reflects an increased probability of success for NRX-100, now estimated at 80%. These developments highlight significant strides and challenges for NRx Pharmaceuticals in its ongoing efforts to innovate within the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.